Newsletter Tool

PM Tracker

Today’s Big News

Aug 20, 2024

Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

Johnson & Johnson to buy heart failure implant company V-Wave for up to $1.7B

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline tinkering continues

Roche regains reputation crown among rare disease patient groups, with Amgen close behind

Teva faces fresh Copaxone kickbacks case from Medicare providers as it defends against DOJ claims

Featured

Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

By Fraiser Kansteiner

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.

Johnson & Johnson to buy heart failure implant company V-Wave for up to $1.7B

By Heather Landi

Johnson & Johnson said Tuesday it will buy heart failure implant company V-Wave in a deal worth a potential $1.7 billion.

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline tinkering continues

By Nick Paul Taylor

Merck & Co. is continuing to tinker with its antibody-drug conjugate alliance with Kelun-Biotech, agreeing to pay $37.5 million to take up its option on one candidate while returning the rights to another asset.

Roche regains reputation crown among rare disease patient groups, with Amgen close behind

By Andrea Park

After being ousted from the top spot last year, Roche has clawed its way back to dominance among rare disease patient groups’ assessments of drugmaker reputations.

Teva faces fresh Copaxone kickbacks case from Medicare providers as it defends against DOJ claims

By Zoey Becker

The new lawsuit, filed in a Kansas court, comes as Teva defends against similar allegations made by the U.S. government.

Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer

By Angus Liu

A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.

Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA

By James Waldron

Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney disease-focused biotech will use to take its lead candidate through the final stages of clinical development.

Lilly adds to tirzepatide's impressive pedigree with new data showing the med helps stave off diabetes

By Fraiser Kansteiner

Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.

Pain medicine biotech Latigo taps CRO founder for CMO role

By Gabrielle Masson

Pain-medicine-focused Latigo Biotherapeutics is welcoming CRO founder Neil Singla, M.D., aboard as chief medical officer.

Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC

By James Waldron

Denmark’s Adcendo is the latest biotech to go big in an antibody-drug conjugate (ADC) deal, signing off on $1 billion in biobucks to get the ex-China rights to a preclinical candidate from Multitude Therapeutics.

AbbVie launches new Skyrizi commercial after topping TV drug ad spenders’ ranking in July

By Ben Adams

AbbVie continues to be top of the TV drug ad spenders as its immunology blockbuster Skyrizi dominates this year’s iSpot roundup. After taking the top spot again last month the Big Pharma is running another new ad.

Fierce podcasts

Don’t miss an episode

The TROP2 race for supremacy

In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

A closer look at Fierce Biotech's Fierce 15

What the data says about the telehealth market

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.